Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium triple viable tablets
- Development stage
- Unknown
- Lead developer
- Shanghai Xinyi Bailuda Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium triple viable tablets is a probiotic combination product containing live *Bifidobacterium longum*, *Lactobacillus acidophilus*, and *Enterococcus faecalis*. It is a live biotherapeutic product primarily used to treat intestinal dysbiosis and associated gastrointestinal symptoms such as diarrhea, constipation, and abdominal distension. The formulation works by colonizing the gastrointestinal tract with beneficial bacteria, which helps restore the balance of the intestinal flora, inhibits the growth of pathogenic bacteria, and supports the intestinal mucosal barrier. In clinical research, it is being evaluated for its potential metabolic benefits, including improving glycemic control, lipid profiles, and systemic inflammation in patients with type 2 diabetes mellitus and obesity, particularly when used as an adjunct to sodium-glucose cotransporter 2 (SGLT2) inhibitors like dapagliflozin.
- Brand names
- BIFICOPeifeikang
- Other names
- Bifidobacterium triple viable tabletsBifidobacterium, Lactobacillus and Enterococcus Triple Viable TabletsBifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis triple viable tabletsBifidobacterium triple viable preparation
Beyond the preview
Go deeper on bifidobacterium triple viable tablets.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium triple viable tablets.